Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence-Reference-Cited by-同舟云学术

Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence

Published:2024-06-11 Issue:20 Volume:20 Page:1401-1413
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Cervantes Andres¹²,Tabernero Josep³,Garcia-Carbonero Rocio⁴,Sastre Javier⁵,Feliu Jaime⁶,Carmen Guillén-Ponce ⁷,Paredes Beatriz García⁵,Carral Alberto⁸,Muñoz Jorge⁹

Affiliation:

1. Medical Oncology Department, Biomedical Research Institute INCLIVA, Hospital Clínico de Valencia, Universidad de Valencia, Valencia, Spain

2. CIBERONC, Instituto de Salud Carlos III, Madrid, Spain

3. Medical Oncology Department, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain

4. Medical Oncology Department, Hospital Universitario 12 de Octubre, Imas12, UCM, CIBERONC, Madrid, Spain

5. Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain

6. Medical Oncology Department, Hospital Universitario La Paz, IDIPAZ, CIBERONC, Cátedra UAM-AMGEN, Madrid, Spain

7. Medical Oncology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain

8. Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain

9. Medical Oncology Department, Hospital San Pedro de Alcántara, Cáceres, Spain

Funder

Bayer HealthCare

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14796694.2024.2340422

Reference37 articles.

1. World Health Organization; International Agency for Research on Cancer. Globocan 2020 Spain cancer fact sheet. 2020. [accessed 2023 August 21]. Available at: https://gco.iarc.fr/today/data/factsheets/populations/724-spain-fact-sheets.pdf

2. Cancer Statistics, 2021

3. Diagnosis and Treatment of Metastatic Colorectal Cancer

4. Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit

5. Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice